| Recruitment status | Completed |
| Unique ID issued by UMIN | C000000340 |
| Receipt No. | R000000439 |
| Official scientific title of the study | Effects of phosphodiesterase V (sildenafil) on pulmonary arterial hypertension |
| Date of disclosure of the study information | 2006/03/01 |
| Last modified on | 2017/03/08 (Ver. 12) |
| Basic information | ||
| Official scientific title of the study | Effects of phosphodiesterase V (sildenafil) on pulmonary arterial hypertension | |
| Title of the study (Brief title) | Effects of sildenafil on pulmonary arterial hypertension | |
| Region |
|
|
| Condition | ||
| Condition | Pulmonary arterial hypertension | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To prove hemodynamic effects and safety of sildenafil in patients with pulmonary arterial hypertention |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase II,III |
| Assessment | |
| Primary outcomes | Decrease in pulmonary arterial pressure, pulmonary vascular resistance and increase in cardiac output at 24 weeks after allocation of patients |
| Key secondary outcomes | Improvement of exercise tolerance
(anaerobic threshold and peak VO2) assessed by cardiopulmonary exercise testing |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Treatment with sildenafil 25mg three times daily for 24 weeks | |
| Interventions/Control_2 | Treatment with prior therapy without sildenafil for 24 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients with pulmonary arterial hypertension
2. Patients in WHO functional class II-IV and with estimated right ventricular systolic pressure (transtricuspid valve pressure gradient+10)>40mmHg under prior therapy 3. Patients with informed concent |
|||
| Key exclusion criteria | 1. Patients with PCWP>15mmHg
2. Pregnat women or women of childbearing potential or brestfeeding 3. Patients who are being treated with medicines that contain nitrates 4. Patients who are being treated with phosphodiesterase inhibitors other than sildenafil 5. Patients who are otherwise judged inappropriate for inclusion in the study by the investigators |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Atsushi Yao |
| Organization | The University of Tokyo Hospital |
| Division name | Division of cardiovascular internal medicine |
| Address | 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan |
| TEL | 03-3815-5411(33076) |
| Public contact | |
| Name of contact person | Atsushi Yao |
| Organization | The University of Tokyo Hospital |
| Division name | Division of cardiovascular internal medicine |
| Address | 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan |
| TEL | 03-3815-5411(33076) |
| Homepage URL | |
| YAOA-INT@h.u-tokyo.ac.jp | |
| Sponsor | |
| Institute | Division of cardiovascular internal medicine, The University of Tokyo Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Division of cardiovascular internal medicine, The University of Tokyo Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Partially published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000000439 |